The food allergy market is projected to experience significant growth in the coming years, driven by the adoption of recently approved therapies and promising emerging treatments such as Viaskin (DBV712) Peanut Patch (DBV Technologies), PVX108 (Aravax), Remibrutinib (Novartis), SLIT tablet (ALK-Abello), RPT904 (RAPT Therapeutics), ANAPHYLM (epinephrine sublingual film) (Aquestive Therapeutics), and others, alongside increasing diagnoses and rising healthcare costs.
DelveInsight’s Food Allergy Market Insights report offers an in-depth analysis of current treatment practices, emerging food allergy therapies, market share of individual drugs, and the present and forecasted food allergy market size from 2020 to 2034, covering leading markets such as the US, EU4, UK, and Japan.
Food Allergy Market Summary
- The food allergy market size in the leading markets was estimated at USD 3 billion in 2024.
- The United States accounted for the largest share, approximately 79% of the total 7MM market in 2024, ahead of the EU4 (Germany, France, Italy, and Spain), the UK, and Japan.
- In 2024, among existing therapies, Epinephrine generated the highest revenue in the US, reaching nearly USD 1.4 billion.
- According to DelveInsight’s 2024 assessment, the 7MM had around 60 million diagnosed prevalent cases of food allergy.
- Key companies actively developing innovative food allergy treatments include DBV Technologies, Aquestive Therapeutics, Novartis, Aravax, RAPT Therapeutics, ALK-Abello, Allergy Therapeutics, Bryn Pharma, Intrommune Therapeutics, Regeneron Pharmaceuticals, and others.
- Emerging therapies in clinical development include Viaskin (DBV712) peanut patch, ANAPHYLM (epinephrine sublingual film), Remibrutinib (LOU064), PVX108, RPT904, SLIT-tablet, VLP Peanut, NDS1C (epinephrine nasal spray), INT301, LYNOZYFIC (linvoseltamab) + DUPIXENT (dupilumab), among others.
- By 2034, ANAPHYLM is expected to generate the highest revenue among emerging therapies in the 7MM.
Explore which food allergy therapies are poised to capture the market share @ Food Allergy Market Report
Key Factors Driving the Growth of the Food Allergy Market
Rising Prevalence of Food Allergies
The global rise in food allergies is a major growth driver. In 2024, the US had around 36 million diagnosed cases. Factors contributing to this increase include skin sensitization and early-life atopic eczema, which are strongly associated with the development of food allergies.
PALFORZIA’s Oral Administration Advantage
PALFORZIA’s oral delivery offers a convenient alternative to traditional subcutaneous, intradermal, or epicutaneous therapies, potentially improving patient adherence and reducing the burden on healthcare systems.
Emerging Opportunities in the Adult Food Allergy Market
The adult food allergy segment represents an untapped opportunity, as currently only one therapy—Novartis’ Remibrutinib—is under evaluation, indicating significant growth potential.
Strong Pipeline Activity
The food allergy treatment pipeline is robust, with active clinical trials led by Aquestive Therapeutics (ANAPHYLM), DBV Technologies (Viaskin DBV712 peanut patch), Novartis (Remibrutinib), Aravax (PVX108), ALK-Abello (SLIT-tablet), InnoUp Farma (INP20), and others.
Food Allergy Market Analysis
Currently available treatment options include immunotherapies, such as oral dose escalation with allergenic food proteins or the FDA-approved peanut allergen powder, and biologic therapies like XOLAIR (omalizumab), administered subcutaneously. Other desensitization approaches, including sublingual (SLIT) and epicutaneous (EPIT) therapies, are in development.
Traditional management focuses on strict allergen avoidance and emergency interventions using epinephrine autoinjectors (EpiPen, Auvi-Q, Adrenaclick), which address acute reactions but do not offer long-term immune control.
Key approved therapies providing clinical benefits include PALFORZIA (peanut allergen powder), XOLAIR (omalizumab), and NEFFY (epinephrine nasal spray). PALFORZIA targets peanut allergy specifically, while XOLAIR is indicated for multiple allergens.
Several companies are advancing novel therapies, including DBV Technologies (Viaskin), Novartis (Remibrutinib), Aravax (PVX108), ALK-Abelló (SLIT-tablet), Allergy Therapeutics (VLP Peanut), and RAPT Therapeutics (RPT904), highlighting strong innovation and commitment to addressing unmet needs in food allergy care.
Learn more about food allergy treatment options @ Food Allergy Treatment Market
Food Allergy Competitive Landscape
Emerging therapies in development, such as Viaskin (DBV712) Peanut Patch, PVX108, Remibrutinib, SLIT tablet, RPT904, and ANAPHYLM, are expected to reshape the market.
- DBV Technologies’ Viaskin Peanut: An epicutaneous immunotherapy delivering trace peanut protein via skin patch to induce desensitization. Currently in Phase III trials for children aged 4–7 years, with top-line results expected from the VITESSE trial (NCT05741476) in Q4 2025.
- Aravax’s PVX108: Next-generation immunotherapy using engineered peptides to modulate T-cell responses, currently in Phase II trials for children and adolescents with peanut allergy.
- RAPT Therapeutics’ Ozureprubart: Long-acting anti-IgE monoclonal antibody designed to block free and cell-bound IgE, showing improved pharmacokinetics and pharmacodynamics versus omalizumab in early studies.
- Aquestive Therapeutics’ ANAPHYLM: Oral epinephrine sublingual film using proprietary PharmFilm® technology, targeting emergency treatment of Type 1 allergic reactions, including anaphylaxis, as an alternative to injectables.
The launch of these innovative therapies is expected to transform the food allergy market, establishing new standards of care and creating opportunities for medical and economic growth.
Discover the latest emerging therapies for food allergy @ Food Allergy Medication
Recent Developments in the Food Allergy Market
- October 2025: RAPT Therapeutics initiated the prestIgE Phase 2b trial of Ozureprubart across ~30 sites in the U.S., Canada, and Australia for IgE-mediated food allergies.
- October 2025: Aquestive Therapeutics received two new U.S. patents covering ANAPHYLM.
- March 2025: FDA approved NEFFY for Type I allergic reactions, including anaphylaxis, in children aged 4–15 kg, marking the first major epinephrine delivery innovation in over 35 years.
- March 2025: Allergy Therapeutics reported that the PROTECT trial is progressing as planned, with topline data expected in summer 2025.
- March 2025: DBV Technologies reached an understanding with the FDA regarding BLA submission for Viaskin Peanut Patch in children aged 4–7 years, accelerating the timeline to H1 2026.
What is Food Allergy?
Food allergy occurs when the immune system reacts abnormally to specific food proteins, either via IgE-mediated or non-IgE-mediated pathways. IgE-mediated allergies are a major global health concern, affecting millions and impacting daily life. Common allergens include milk, eggs, fish, shellfish, tree nuts, peanuts, wheat, and soy. Reactions may involve the skin, gastrointestinal tract, cardiovascular system, or respiratory system, causing hives, vomiting, coughing, wheezing, throat or tongue swelling, weak pulse, dizziness, or, in severe cases, potentially fatal anaphylaxis.
Food Allergy Epidemiology Segmentation
The epidemiology section details historical and current patient populations and forecast trends across leading markets. In 2024, within the 7MM, adult cases were more severe (25 million) than mild-to-moderate, with numbers expected to rise by 2034.
The food allergy report provides analysis from 2020–2034, segmented into:
- Total diagnosed prevalent cases of food allergy
- Allergen-specific diagnosed prevalent cases
- Gender-specific diagnosed prevalent cases
- Severity-specific diagnosed prevalent cases
Download the report to explore comprehensive food allergy management @ Food Allergy Treatment Options
Scope of the Food Allergy Market Report
- Food Allergy Therapeutic Assessment: Analysis of currently marketed and emerging food allergy therapies
- Food Allergy Market Dynamics: Integrated assessment of emerging food allergy drugs and their market impact
- Competitive Intelligence Analysis: SWOT evaluation and market entry strategies of key players
- Food Allergy Market Unmet Needs: Insights from KOLs, analysts, and perspectives on market access and reimbursement
Explore detailed information on food allergy drugs in development @ Food Allergy Clinical Trials
About DelveInisght
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions.
